In contrast, non‐specific inhibition of EZH2/1 in ER+ breast cancer cells may induce a more robust response over tazemetostat delivery alone, as EZH1 may negatively regulate NKILA under EZH2 inhibition. The gene discussed is EZH1; the disease is breast carcinoma.